\contentsline {chapter}{\numberline {1}Motivation and Background}{4}{chapter.1}%
\contentsline {section}{\numberline {1.1}Introduction: Closing Critical Gaps in CRISPR Safety and Efficiency}{4}{section.1.1}%
\contentsline {subsection}{\numberline {1.1.1}The CRISPR Revolution and Clinical Reality}{4}{subsection.1.1.1}%
\contentsline {subsection}{\numberline {1.1.2}Five Critical Bottlenecks in Current Models}{4}{subsection.1.1.2}%
\contentsline {subsection}{\numberline {1.1.3}The Proposed Solution: CRISPRO-MAMBA-X}{5}{subsection.1.1.3}%
\contentsline {subsection}{\numberline {1.1.4}Dissertation Overview}{5}{subsection.1.1.4}%
\contentsline {section}{\numberline {1.2}Mathematical Foundations and Theoretical Framework}{6}{section.1.2}%
\contentsline {subsection}{\numberline {1.2.1}Information Theoretic Foundations}{6}{subsection.1.2.1}%
\contentsline {subsection}{\numberline {1.2.2}Computational Complexity: Overcoming the $O(N^2)$ Barrier}{6}{subsection.1.2.2}%
\contentsline {subsection}{\numberline {1.2.3}Conformal Prediction: The Universal Coverage Guarantee}{7}{subsection.1.2.3}%
\contentsline {subsection}{\numberline {1.2.4}Generalization Bounds}{7}{subsection.1.2.4}%
\contentsline {section}{\numberline {1.3}State-of-the-Art and Critical Limitations}{7}{section.1.3}%
\contentsline {subsection}{\numberline {1.3.1}Evolution of CRISPR Prediction (2014-2025)}{7}{subsection.1.3.1}%
\contentsline {subsection}{\numberline {1.3.2}The Persistence of Unexplained Variance}{8}{subsection.1.3.2}%
\contentsline {subsection}{\numberline {1.3.3}Critical Gaps in SOTA}{8}{subsection.1.3.3}%
\contentsline {chapter}{\numberline {2}The CRISPRO-MAMBA-X Architecture}{9}{chapter.2}%
\contentsline {section}{\numberline {2.1}Epigenomics Integration Framework}{9}{section.2.1}%
\contentsline {subsection}{\numberline {2.1.1}The Five Dimensions of Chromatin Accessibility}{9}{subsection.2.1.1}%
\contentsline {subsection}{\numberline {2.1.2}Attention-Weighted Multimodal Fusion}{9}{subsection.2.1.2}%
\contentsline {section}{\numberline {2.2}Mamba: Linear-Time Modeling of Megabase-Scale Chromatin}{10}{section.2.2}%
\contentsline {subsection}{\numberline {2.2.1}Graph-Coupled State Space Duality}{10}{subsection.2.2.1}%
\contentsline {subsection}{\numberline {2.2.2}Biophysical Kinetic Decoding}{11}{subsection.2.2.2}%
\contentsline {subsection}{\numberline {2.2.3}Selective State Space Models}{11}{subsection.2.2.3}%
\contentsline {subsection}{\numberline {2.2.4}Computational Feasibility}{11}{subsection.2.2.4}%
\contentsline {subsection}{\numberline {2.2.5}Epigenetically Modulated Memory}{12}{subsection.2.2.5}%
\contentsline {chapter}{\numberline {3}Safety and Uncertainty Quantification}{14}{chapter.3}%
\contentsline {section}{\numberline {3.1}Off-Target Safety Prediction Methodology}{14}{section.3.1}%
\contentsline {subsection}{\numberline {3.1.1}The Four Pillars of Off-Target Safety}{14}{subsection.3.1.1}%
\contentsline {subsection}{\numberline {3.1.2}Genome-Wide Risk Stratification}{15}{subsection.3.1.2}%
\contentsline {section}{\numberline {3.2}Conformal Prediction for Clinical Risk Stratification}{15}{section.3.2}%
\contentsline {subsection}{\numberline {3.2.1}The Universal Coverage Guarantee}{16}{subsection.3.2.1}%
\contentsline {subsection}{\numberline {3.2.2}Mondrian Conformal Prediction}{16}{subsection.3.2.2}%
\contentsline {subsection}{\numberline {3.2.3}Clinical Decision Support}{17}{subsection.3.2.3}%
\contentsline {chapter}{\numberline {4}Proposed Validation and Anticipated Results}{18}{chapter.4}%
\contentsline {section}{\numberline {4.1}Proposed Experimental Validation Strategy}{18}{section.4.1}%
\contentsline {subsection}{\numberline {4.1.1}Phase 1: Computational Benchmarking (Anticipated)}{18}{subsection.4.1.1}%
\contentsline {subsection}{\numberline {4.1.2}Simulated Ablation Analysis}{19}{subsection.4.1.2}%
\contentsline {subsection}{\numberline {4.1.3}Phase 2: Retrospective Validation on External Cohorts}{19}{subsection.4.1.3}%
\contentsline {section}{\numberline {4.2}Anticipated Generalization and Domain Analysis}{19}{section.4.2}%
\contentsline {subsection}{\numberline {4.2.1}Predicted Domain Shift Impact}{19}{subsection.4.2.1}%
\contentsline {subsection}{\numberline {4.2.2}Mitigation Strategy}{20}{subsection.4.2.2}%
\contentsline {chapter}{\numberline {5}Clinical Translation and Conclusion}{21}{chapter.5}%
\contentsline {section}{\numberline {5.1}System Architecture and Clinical Deployment}{21}{section.5.1}%
\contentsline {subsection}{\numberline {5.1.1}End-to-End Clinical System}{21}{subsection.5.1.1}%
\contentsline {subsection}{\numberline {5.1.2}FDA Regulatory Pathway}{21}{subsection.5.1.2}%
\contentsline {subsection}{\numberline {5.1.3}Data Availability \& Usage Protocols}{22}{subsection.5.1.3}%
\contentsline {subsection}{\numberline {5.1.4}Competitive Benchmarking Data}{22}{subsection.5.1.4}%
\contentsline {subsection}{\numberline {5.1.5}Clinical Decision Support Interface}{23}{subsection.5.1.5}%
\contentsline {section}{\numberline {5.2}Beyond Mamba: Neural Architecture Search}{23}{section.5.2}%
\contentsline {subsection}{\numberline {5.2.1}Search Methodology}{23}{subsection.5.2.1}%
\contentsline {subsection}{\numberline {5.2.2}The Pareto Frontier}{23}{subsection.5.2.2}%
\contentsline {subsection}{\numberline {5.2.3}Optimal Architecture Selection}{23}{subsection.5.2.3}%
\contentsline {section}{\numberline {5.3}Conclusion and Future Directions}{24}{section.5.3}%
\contentsline {subsection}{\numberline {5.3.1}Summary of Contributions}{24}{subsection.5.3.1}%
\contentsline {subsection}{\numberline {5.3.2}Future Roadmap}{24}{subsection.5.3.2}%
\contentsline {subsection}{\numberline {5.3.3}Final Vision}{25}{subsection.5.3.3}%
\contentsline {chapter}{\numberline {6}Discussion and Contributions}{26}{chapter.6}%
\contentsline {section}{\numberline {6.1}Discussion of Anticipated Impact}{26}{section.6.1}%
\contentsline {subsection}{\numberline {6.1.1}Interpretation of Architectural Innovations}{26}{subsection.6.1.1}%
\contentsline {subsection}{\numberline {6.1.2}Clinical Implications of Conformal Prediction}{26}{subsection.6.1.2}%
\contentsline {section}{\numberline {6.2}Summary of Contributions}{27}{section.6.2}%
\contentsline {section}{\numberline {6.3}Limitations and Future Work}{28}{section.6.3}%
\contentsline {section}{\numberline {6.4}Conclusion}{29}{section.6.4}%
